Position in AZN
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$412,958,167
New position
Shares Held
2,093,896
first reported quarter
Ownership
0.135%
of shares outstanding
% of Portfolio
0.44%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 83.65635160485525.ToString("F0")%
Shared 0.ToString("F0")%
None 16.343648395144744.ToString("F0")%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Boston Partners holds $2,940,069,361 across 12 Drug Manufacturers - General names. AZN ranks #3 (14.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
3,434,210 | $746,906,331 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
4,255,122 | $593,036,351 | |
| 3 | AZN |
Astrazeneca PLC
This page
|
2,093,896 | $412,958,167 | |
| 4 | JNJ |
Johnson & Johnson
|
1,558,577 | $380,978,561 | |
| 5 | BIIB |
Biogen Inc.
|
1,700,078 | $311,675,298 | |
| 6 | AMGN |
Amgen Inc
|
643,175 | $226,301,122 | |
| 7 | SNY |
Sanofi
|
3,599,284 | $173,413,502 | |
| 8 | MRK |
Merck & Co., Inc.
|
641,766 | $77,198,031 |
All Filings in AZN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $412,958,167 | 2,093,896 | Shares | Defined | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||